Cargando…

The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases

BACKGROUND: As new infectious diseases (ID) emerge and others continue to mutate, there remains an imminent threat, especially for vulnerable individuals. Yet no generalizable framework exists to identify the at-risk group prior to infection. Metabolomics has the advantage of capturing the existing...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yulu, Mendez, Kevin, Begum, Sofina, Dean, Emily, Chatelaine, Haley, Braisted, John, Fangal, Vrushali D., Cote, Margaret, Huang, Mengna, Chu, Su H., Stav, Meryl, Chen, Qingwen, Prince, Nicole, Kelly, Rachel, Christopher, Kenneth B., Diray-Arce, Joann, Mathé, Ewy A., Lasky-Su, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518609/
https://www.ncbi.nlm.nih.gov/pubmed/37734204
http://dx.doi.org/10.1016/j.ebiom.2023.104791
_version_ 1785109552874651648
author Chen, Yulu
Mendez, Kevin
Begum, Sofina
Dean, Emily
Chatelaine, Haley
Braisted, John
Fangal, Vrushali D.
Cote, Margaret
Huang, Mengna
Chu, Su H.
Stav, Meryl
Chen, Qingwen
Prince, Nicole
Kelly, Rachel
Christopher, Kenneth B.
Diray-Arce, Joann
Mathé, Ewy A.
Lasky-Su, Jessica
author_facet Chen, Yulu
Mendez, Kevin
Begum, Sofina
Dean, Emily
Chatelaine, Haley
Braisted, John
Fangal, Vrushali D.
Cote, Margaret
Huang, Mengna
Chu, Su H.
Stav, Meryl
Chen, Qingwen
Prince, Nicole
Kelly, Rachel
Christopher, Kenneth B.
Diray-Arce, Joann
Mathé, Ewy A.
Lasky-Su, Jessica
author_sort Chen, Yulu
collection PubMed
description BACKGROUND: As new infectious diseases (ID) emerge and others continue to mutate, there remains an imminent threat, especially for vulnerable individuals. Yet no generalizable framework exists to identify the at-risk group prior to infection. Metabolomics has the advantage of capturing the existing physiologic state, unobserved via current clinical measures. Furthermore, metabolomics profiling during acute disease can be influenced by confounding factors such as indications, medical treatments, and lifestyles. METHODS: We employed metabolomic profiling to cluster infection-free individuals and assessed their relationship with COVID severity and influenza incidence/recurrence. FINDINGS: We identified a metabolomic susceptibility endotype that was strongly associated with both severe COVID (OR(ICUadmission) = 6.7, p-value = 1.2 × 10(−08), OR(mortality) = 4.7, p-value = 1.6 × 10(−04)) and influenza (OR(incidence) = 2.9; p-values = 2.2 × 10(−4), β(recurrence) = 1.03; p-value = 5.1 × 10(−3)). We observed similar severity associations when recapitulating this susceptibility endotype using metabolomics from individuals during and after acute COVID infection. We demonstrate the value of using metabolomic endotyping to identify a metabolically susceptible group for two–and potentially more–IDs that are driven by increases in specific amino acids, including microbial-related metabolites such as tryptophan, bile acids, histidine, polyamine, phenylalanine, and tyrosine metabolism, as well as carbohydrates involved in glycolysis. INTERPRETATIONS: These metabolites may be identified prior to infection to enable protective measures for these individuals. FUNDING: The Longitudinal EMR and Omics COVID-19 Cohort (LEOCC) and metabolomic profiling were supported by the 10.13039/100000050National Heart, Lung, and Blood Institute and the Intramural Research Program of the 10.13039/100006108National Center for Advancing Translational Sciences, National Institutes of Health.
format Online
Article
Text
id pubmed-10518609
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105186092023-09-26 The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases Chen, Yulu Mendez, Kevin Begum, Sofina Dean, Emily Chatelaine, Haley Braisted, John Fangal, Vrushali D. Cote, Margaret Huang, Mengna Chu, Su H. Stav, Meryl Chen, Qingwen Prince, Nicole Kelly, Rachel Christopher, Kenneth B. Diray-Arce, Joann Mathé, Ewy A. Lasky-Su, Jessica eBioMedicine Articles BACKGROUND: As new infectious diseases (ID) emerge and others continue to mutate, there remains an imminent threat, especially for vulnerable individuals. Yet no generalizable framework exists to identify the at-risk group prior to infection. Metabolomics has the advantage of capturing the existing physiologic state, unobserved via current clinical measures. Furthermore, metabolomics profiling during acute disease can be influenced by confounding factors such as indications, medical treatments, and lifestyles. METHODS: We employed metabolomic profiling to cluster infection-free individuals and assessed their relationship with COVID severity and influenza incidence/recurrence. FINDINGS: We identified a metabolomic susceptibility endotype that was strongly associated with both severe COVID (OR(ICUadmission) = 6.7, p-value = 1.2 × 10(−08), OR(mortality) = 4.7, p-value = 1.6 × 10(−04)) and influenza (OR(incidence) = 2.9; p-values = 2.2 × 10(−4), β(recurrence) = 1.03; p-value = 5.1 × 10(−3)). We observed similar severity associations when recapitulating this susceptibility endotype using metabolomics from individuals during and after acute COVID infection. We demonstrate the value of using metabolomic endotyping to identify a metabolically susceptible group for two–and potentially more–IDs that are driven by increases in specific amino acids, including microbial-related metabolites such as tryptophan, bile acids, histidine, polyamine, phenylalanine, and tyrosine metabolism, as well as carbohydrates involved in glycolysis. INTERPRETATIONS: These metabolites may be identified prior to infection to enable protective measures for these individuals. FUNDING: The Longitudinal EMR and Omics COVID-19 Cohort (LEOCC) and metabolomic profiling were supported by the 10.13039/100000050National Heart, Lung, and Blood Institute and the Intramural Research Program of the 10.13039/100006108National Center for Advancing Translational Sciences, National Institutes of Health. Elsevier 2023-09-19 /pmc/articles/PMC10518609/ /pubmed/37734204 http://dx.doi.org/10.1016/j.ebiom.2023.104791 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Chen, Yulu
Mendez, Kevin
Begum, Sofina
Dean, Emily
Chatelaine, Haley
Braisted, John
Fangal, Vrushali D.
Cote, Margaret
Huang, Mengna
Chu, Su H.
Stav, Meryl
Chen, Qingwen
Prince, Nicole
Kelly, Rachel
Christopher, Kenneth B.
Diray-Arce, Joann
Mathé, Ewy A.
Lasky-Su, Jessica
The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases
title The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases
title_full The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases
title_fullStr The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases
title_full_unstemmed The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases
title_short The value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases
title_sort value of prospective metabolomic susceptibility endotypes: broad applicability for infectious diseases
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518609/
https://www.ncbi.nlm.nih.gov/pubmed/37734204
http://dx.doi.org/10.1016/j.ebiom.2023.104791
work_keys_str_mv AT chenyulu thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT mendezkevin thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT begumsofina thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT deanemily thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT chatelainehaley thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT braistedjohn thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT fangalvrushalid thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT cotemargaret thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT huangmengna thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT chusuh thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT stavmeryl thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT chenqingwen thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT princenicole thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT kellyrachel thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT christopherkennethb thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT dirayarcejoann thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT matheewya thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT laskysujessica thevalueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT chenyulu valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT mendezkevin valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT begumsofina valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT deanemily valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT chatelainehaley valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT braistedjohn valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT fangalvrushalid valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT cotemargaret valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT huangmengna valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT chusuh valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT stavmeryl valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT chenqingwen valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT princenicole valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT kellyrachel valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT christopherkennethb valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT dirayarcejoann valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT matheewya valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases
AT laskysujessica valueofprospectivemetabolomicsusceptibilityendotypesbroadapplicabilityforinfectiousdiseases